eEF2/eEF2k as therapeutic target for treating TNF-alpha-related diseases. The present invention comprises inhibitors of eEF2 and/or activators of eEF2 kinase for use in the treatment of TNF-alpha-related diseases, preferably liver diseases. Consequently this invention can be included either in the pharmaceutical, biotechnological or medical field.